FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Gilead Sciences' HIV Drug Shows Weaker Persistence Rates

      Gilead Sciences has been noted for potentially exceeding consensus estimates for the first quarter. However, recent analysis indicates that the persistence rates of its HIV drug are weaker than anticipated nine months following its launch.

      The findings suggest that while initial sales may be strong, the long-term retention of patients on the medication is not meeting expectations. This could impact future revenue projections for Gilead's HIV treatment portfolio.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud